Building The Future Of Cancer Immunotherapy Through Allogeneic NK Cell Innovation | Audience Q&A
Source: Cell & Gene
In this segment of Cell & Gene Live, Building the Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, Raphael Ognar, President, CEO, and Co-Founder of NKILT Therapeutics and Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics, provided detailed responses to the audience questions about challenges in donor variability for allogeneic NK cell therapies, rigorous patient safety criteria focused on health status, cryopreservation, and more.